Board of Directors

Chad Brinkley

Chad Brinkley

Chairman, President, and CEO Chad Brinkley is an entrepreneur that has primarily focused on the Aerospace & Defense Market with a concentration in space. He founded several companies in this arena that provide solutions to NASA, Department of Defense, National Reconnaissance Office and commercial space companies. His interest in the biotechnology world began at the Center for The Advancement of Science in Space (CASIS) that manages the International Space Station National Laboratory (ISS-NL). In this role he managed the technology development portfolio as a member of the business development team. Through this experience of flying many different science project to the ISS he became interested in joining the C3D team and licensing drug delivery system technologies from the Houston Methodist Research Institute (HMRI).

Glauco R. Souza, Ph.D.

Glauco R. Souza, PhD, Co-Founder, Director, former President and CSO of Nano3D Biosciences, and now Director of Global Business Development and Innovation at Greiner Bio-one (GBO). The inventor or co-inventor of all eleven patents related to magnetic 3D cell culture, Glauco is a major influence in the field of 3D cell culture. After GBO IP acquisition, Dr. Souza took the position at GBO to oversee 3D cell culture operations and marketing globally. He is instrumental in any needed product and technical support to be provided by GBO.

He is was a former Adjunct Assistant Professor at University of Texas Health Science Center at Houston. His work in 3D cell culture was selected for the Short List of the 2017 Lush Prize for outstanding research producing an effective non-animal safety test Prior to co-founding Nano3D BioSciences, he was an Odyssey Scholar at The University of Texas M. D. Anderson Cancer Center. Glauco R. Souza has a B.S. in Chemistry, and M.S. and Ph.D. in Physical Chemistry from The George Washington University.

Thomas C. Killian, Ph.D.

Thomas C. Killian, Ph.D. received a BA in Physics in 1991 from Harvard University, and then attended Cambridge University on a Marshall Scholarship, where he earned an MPhil in physical chemistry in 1993. He received his PhD in atomic physics at the Massachusetts Institute of Technology in 1999, and then completed a post-doctoral fellowship at the National Institute of Standards and Technology. In 2001, Dr. Killian became an Assistant Professor of Physics and Astronomy at William Marsh Rice University where he conducts research on the properties of matter at temperatures as low as a few billionths of a degree above absolute zero.

He served as the Chair of the Department of Physics and Astronomy from 2012-2016 and is currently the Associate Dean for Strategic Planning in the Wiess School of Natural Sciences at Rice. He is also a co-founder and Director of ChemoSen3D, Inc., which is developing assays that use a patient’s own cells to identify the optimal therapeutic treatment for cancer.

Leonardo Dias, MBA

Leonardo Dias is a seasoned professional with a rich background in finance and business leadership. He holds an MBA in International Finance from The George Washington University and a Bachelor’s degree in Economics from Universidade de Brasília. Leonardo’s career spans over two decades, with significant experience in various roles. He served as the Director at BrScan for over two years and was a Co-Owner for 11 years. Prior to that, he was a Partner at IBET Consulting for nearly a decade and held key positions such as Chief Financial Officer and Investor Relations Officer at Equatorial Energia S.A. His early career includes a six-year stint as Controller and IR Director at Telemig Celular. Leonardo’s extensive experience and academic background make him a valuable addition to ChemoSen3D’s board of directors, where his insights and expertise are expected to contribute significantly to the company’s growth and success.

Matt Lenhart

Matt Lenhart has been an Energy Trader for the last two decades.  He also invests in private companies.  He received his BS from Louisiana State University.

3D Cell Culture  •  Biotechnology  •  Clinical Diagnostics  •  Nanoparticles